Table 2.
Correlated LC-MS masses and proteomics data for coagulopathic venom toxins activities (peak retention times are adapted from Figure 4; SVMP: Snake Venom Metalloproteinase; SVSP: Snake Venom Serine Protease; CTL: C-Type Lectin; kunitz: kunitz-type serine protease inhibitor; PN: Partly Neutralized at 20 μM varespladib; NOI: No Observed Inhibition.
| Species | Peak Retention Time (min) | Peak Activity | Mascot Results Matching the Exact Mass | m/z Values from MS Data | Exact Mass from MS Data | Exact Mass Calculated from Mascot Data | Toxin Class | Varespladib Concentration Needed for Full Inhibition |
|---|---|---|---|---|---|---|---|---|
| B . asper | 23.1–24.2 | Anticoagulation | PA2H2_BOTAS | 1373.368810+ | 13,714.5646 | 13,714.56817 | PLA2 | 0.8 μM |
| 24.2–25.2 | Anticoagulation | PA2HA_BOTAS | 1266.598511+ | 13,912.4649 | 13,896.51308 | PLA2 | 20 μM | |
| 24.2–25.2 | Anticoagulation | PA2H3_BOTAS | 1378.369710+ | 13,765.5812 | 13,765.58896 | PLA2 | 20 μM | |
| 25.2–25.8 | Anticoagulation | PA2B3_BOTAS | 1164.881112+ | 13,957.5333 | 13,957.48720 | PLA2 | 20 μM | |
| 25.2–25.8 | Anticoagulation | PA2A2_BOTAS | – | - | 14,194 | PLA2 | 20 μM | |
| 25.2–25.8 | Anticoagulation | VM2_BOTAS | - | - | 53,564 | SVMP | NOI | |
| 25.0–26.8 | Procoagulation | VSPL_BOTAS | - | - | 28,019 | SVSP | PN | |
| 25.0–26.8 | Procoagulation | VM1B1_BOTAS | - | - | 45,936 | SVMP | PN | |
| 25.4–26.8 | Procoagulation | SLA_BOTAS | - | 7084 | CTL | PN | ||
| C . rhodostoma | 24.3–25.5 | Anticoagulation | PA2BD_CALRH | 1244.110311+ | 13,665.0848 | 13,665.0237 | PLA2 | NOI |
| 24.3–25.5 | Anticoagulation | PA2AB_CALRH | - | - | 14,352 | PLA2 | NOI | |
| 24.3–25.5 | Anticoagulation | VSPF1_CALRH | - | - | 26,570 | SVSP | NOI | |
| 24.3–25.5 | Anticoagulation | SLEA_CALRH | - | - | 15,962 | CTL | NOI | |
| 24.3–25.5 | Anticoagulation | SLEB_CALRH | - | - | 15,190 | CTL | NOI | |
| 24.3–26.6 | Procoagulation | VSPF2_CALRH | - | - | 29,145 | SVSP | PN | |
| 24.9–26.6 | Procoagulation | SLYA_CALRH | - | - | 15,796 | CTL | PN | |
| 24.9–26.6 | Procoagulation | SLYB_CALRH | - | - | 16,770 | CTL | PN | |
| D . acutus | 25.4–25.9 | Anticoagulation | PA2A_DEIAC | - | - | 14,820 | PLA2 | 4 μM |
| 25.4–25.9 | Anticoagulation | SL_DEIAC | - | - | 18,332 | CTL | 4 μM | |
| 26.0–27.2 | Procoagulation | VSP1_DEIAC | - | - | 29,480 | SVSP | PN | |
| 26.0–27.2 | Procoagulation | VSPA_DEIAC | - | - | 26,132 | SVSP | PN | |
| 26.4–27.8 | Procoagulation | SLCB_DEIAC | - | - | 17,133 | CTL | PN | |
| 26.4–27.8 | Procoagulation | VM1AC_DEIAC | - | - | 47,690 | SVMP | PN | |
| 26.4–27.8 | Procoagulation | VM11_DEIAC | - | - | 47,845 | SVMP | PN | |
| 26.4–27.8 | Procoagulation | VM1H5_DEIAC | - | - | 46,518 | SVMP | PN | |
| 26.4–27.8 | Procoagulation | VM3AK_DEIAC | - | - | 69,752 | SVMP | PN | |
| 27.8–28.4 | Procoagulation | VM3A2_DEIAC | - | 27,151 | SVMP | 20 μM | ||
| 27.8–28.4 | Procoagulation | VM3AH_DEIAC | - | 70,721 | SVMP | 20 μM | ||
| D. russelii | 23.4–26.4 | Anticoagulation | PA2B8_DABRR | 1511.69629+ | 13,587.2248 | 13,587.2027 | PLA2 | 20 μM |
| 23.4–26.4 | Anticoagulation | PA2B5_DABRR | – | 13,587 | PLA2 | 20 μM | ||
| 23.4–26.4 | Anticoagulation | PA2B3_DABRR | – | 13,687 | PLA2 | 20 μM | ||
| 26.2–27.6 | Procoagulation | – | - | - | - | - | ||
| E. carinatus | 23.3–23.8 | Anticoagulation | PA2A1_ECHCA | - | - | 16,310 | PLA2 | 0.8 μM |
| 23.8–26.9 | Procoagulation | - | - | - | - | - | ||
| E. ocellatus | 24.4–25.1 | Anticoagulation | PA2A5_ECHOC | 1541.47189+ | 13,856.1382 | 13,856.0665 | PLA2 | 4 μM |
| 26.3–28.2 | Procoagulation | VM3E2_ECHOC | - | - | 69,426 | SVMP | PN | |
| 26.3–28.2 | Procoagulation | VM3E6_ECHOC | - | - | 57,658 | SVMP | PN | |
| 26.3–28.2 | Procoagulation | SL1_ECHOC | - | - | 16,601 | CTL | PN | |
| 26.3–28.2 | Procoagulation | SL124_ECHOC | - | - | 16,882 | CTL | PN | |
| O. scutellatus | 21.7–25.2 | Anticoagulation | PA2TA_OXYSC | - | - | 13,829 | PLA2 | 20 μM |
| 21.7–25.2 | Anticoagulation | PA2TB_OXYSC | - | - | 16,008 | PLA2 | 20 μM | |
| 21.7–25.2 | Anticoagulation | PA21_OXYSC | - | - | 16,898 | PLA2 | 20 μM | |
| 21.7–25.2 | Anticoagulation | PA2TC_OXYSC | - | - | 13,313 | PLA2 | 20 μM | |
| 21.7–25.2 | Anticoagulation | VKT_OXYSC | - | 9711 | kunitz | 20 μM | ||
| 21.7–25.2 | Anticoagulation | VKT3_OXYSC | - | - | 9029 | kunitz | 20 μM |